No Data
No Data
After Losing 22% in the Past Year, Amplitude, Inc. (NASDAQ:AMPL) Institutional Owners Must Be Relieved by the Recent Gain
Key Insights Institutions' substantial holdings in Amplitude implies that they have significant influence over the company's share price A total of 8 investors have a majority stake in the company w
With 49% Ownership, Amplitude, Inc. (NASDAQ:AMPL) Has Piqued the Interest of Institutional Investors
Ability Biologics Anuncia El Cierre De Su Extensión De Financiación Inicial De 18 Millones De Dólares
- Ability Biologics anuncia el cierre de su extensión de financiación inicial de 18 millones de dólares para la generación de inmunomoduladores novedosos y altamente específicosMONTREAL, 18 de j
Ability Biologics Announces the Closing of Its US $18 Million Seed Funding Extension Toward the Generation of Novel, Highly Targeted Immunomodulators
MONTREAL, June 18, 2024 /PRNewswire/ -- Ability Biologics ("Ability") announced the final closing of its seed funding, raising a total of $18 million (US), a financing round led by founding investor
Express News | Amplitude Announced Six Expanded Integrations For Businesses
Amplitude Expands Partner Ecosystem to Help Companies Build Better Products
New integration portal enables partners to quickly and easily build on the Amplitude platform Today, Amplitude, Inc. (NASDAQ:AMPL), a leading digital analytics platform, announced six new and expanded integrations
No Data